• Agilent completed its previously announced acquisition of clinical pathology group Biocare Medical, adding it to the Life Sciences and Diagnostics Markets Group.
• The deal expands Agilent’s pathology portfolio across clinical and research settings.
• The acquisition is expected to lift first-year revenue growth, margins, non-instrument revenue mix.
• EPS accretion is expected about 12 months after closing.
• Expected impact on FY2026 financials is slated for release with Agilent’s third-quarter earnings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260625267055) on June 25, 2026, and is solely responsible for the information contained therein.